Importance: To standardize initial anti-viral therapy for herpes simplex keratitis (HSK).
INTRODUCTION
Herpes simplex keratitis (HSK) is an important cause of unilateral infectious blindness in developed countries due to stromal opacification. 1 One fifth of people with ocular herpes simplex virus (HSV) infection develop corneal stromal disease with the attendant risk of blindness. 2 Farooq and Shukla estimated that the incidence of HSK is 23.3 per 100 000 person-years for developed nations, extrapolating data from epidemiological studies from France and the United States. They also estimated that at least 1.5% of clinically HSK leads to vision worse than 20/200 (World Health Organization definition of severe visual impairment). Therefore, worldwide, the incidence of HSK in 2012 was estimated at about 1.5 million, with 40 000 new cases of severe monocular visual impairment or blindness each year. 1 Despite HSK being an important public health issue, there are limited therapeutic interventions available to reduce complications such as corneal scarring and blindness.
The Herpetic Eye Disease Study (HEDS) clinical trials, published in the 1990s, made a significant contribution to establishing treatment regimens for HSK. [3] [4] [5] [6] [7] Subsequent randomized clinical trials (RCTs) and a Cochrane review have added to the evidence base. 2, 8 For epithelial HSK, evidence supports the use of topical aciclovir 3% five times daily, topical trifluorothymidine 1% 8 times daily or oral aciclovir 400 mg three to five times daily. 2, 8 For stromal HSK without ulceration, the use of a prophylactic anti-viral such as topical trifluorothymidine or oral aciclovir 400 mg twice daily given with 1% prednisolone eye drops (or equivalent topical corticosteroid therapy) every 2 h, then tapered every 1-2 weeks, is supported by evidence. 2, 4 For endothelial HSK, there is not enough clinical trial evidence or guidelines to recommend an appropriate anti-viral dosage. One clinical trial supported the use of an anti-viral agent such as aciclovir 400 mg five times daily plus a topical corticosteroid five times daily, 9 which we use as a guide in our study. To prevent episodes of HSK, aciclovir 400 mg twice daily for at least a year can reduce the rate of epithelial and stromal HSK episodes. 7 The availability and pricing of anti-viral agents varies by geographic location, and resistance patterns vary by patient group. The HEDS group did not examine the use of topical aciclovir, which is widely used in Australia, but not approved in the United States. In contrast, ganciclovir ophthalmic gel 0.15% has been a first-line therapy for epithelial HSK in the United States since 2009 and commercially available in Europe since 1996; but only available in Australia through the Therapeutics Goods Administration Special Access Scheme. Studies have compared ganciclovir 0.15% ophthalmic gel and topical aciclovir, concluding that ganciclovir is as effective as topical aciclovir for the treatment of epithelial HSK, with better tolerance and a lower rate of blurred vision, eye irritation and punctate keratitis. 10, 11 Resistance to anti-viral drugs has been reported mainly in immunocompromised patients. 12, 13 It is not known how closely current treatment patterns follow the evidence from clinical trials. This study examined whether clinical practice in 2012-2013 followed the available clinical evidence for same period of time in a quaternary eye centre in Sydney, Australia.
METHODS
A retrospective case study of patients prescribed antiviral medications for HSK from 1 January 2012 to 31 December 2013 was performed at the Sydney Eye Hospital. Three databases were used to identify patients: diagnostic International Classification of Diseases 10 (ICD-10) coding data, pharmacy and pathology databases (Table 1) . Sydney Eye Hospital pharmacy provided the records of all outpatients and inpatients who were dispensed the oral and topical anti-virals listed in Table 1 . South Eastern Area Laboratory Services (SEALS) provided the details for patients who had had a HSV polymerase chain reaction (PCR) swab performed. A final database including all possible cases of HSK was compiled from the above three data sets after cross-referencing.
Medical records of patients identified via the database search (Table 1) were reviewed and included in the study if they were 18 years of age or older and had anti-viral therapy prescribed for the treatment or prevention of HSK. Patients were excluded if they had an immunological corneal condition, such as peripheral ulcerative keratitis (which is mainly associated with rheumatoid arthritis), an active bacterial co-infection or herpes zoster keratitis, to avoid confounding the diagnosis of HSK.
Study data were collected and managed using REDCap (Research Electronic Data Capture, Nashville, TN, USA) hosted at The University of Sydney. 14 Ethics approval was gained from the South Eastern Sydney Local Health District Human Resources Ethics Committee (approval number HREC 13/296). Data are reported in line with the STROBE statement for observational data. 15 The research adhered to the Tenets of the Declaration of Helsinki.
Data extracted from individual medical records included demographic details such as place of residence 16 ; relevant ophthalmic and medical history; clinical diagnosis; and type, form, dosage and duration of initial anti-viral and topical corticosteroid therapy.
Herpes simplex keratitis classification
The indication for the chosen initial anti-viral therapy (whether therapeutic or prophylactic) and type of HSK were determined based on the clinical findings and medical history documented in the medical notes. When active HSK was present, the anti-viral therapy indication was considered 'therapeutic'. A 'prophylactic' indication was recorded when patients were prescribed anti-virals to prevent further episodes of HSK, due to recurrent disease or following ocular surgery such as corneal transplantation.
For therapeutic indications, the type of HSK was divided into four anatomic subgroups: epithelial, stromal, endothelial and keratouveitis. Inclusion criteria for 'epithelial' HSK subgroup were patients with dendritic or geographical ulceration. Patients were classified as having 'stromal' HSK if they had corneal stromal vascularization, opacity, lipid keratopathy and/or ulceration. The 'endothelial' HSK subgroup included patients with stromal oedema and keratic precipitates. 2 The 'keratouveitis' subgroup included patients with corneal oedema, stromal keratitis, keratitic precipitates and anterior chamber cells. [17] [18] [19] Clinical trial evidence in HSV keratitis A review of the literature, at the time of study commencement (March 2014) was used to identify available evidence for the management of HSK from RCTs. The following 'guidelines' were determined to compare with the findings of our study:
• For epithelial HSK: topical aciclovir 3% five times daily, topical trifluorothymidine 1% eight times daily, or oral aciclovir 400 mg three to five times daily.
2,8
• For stromal HSK without ulceration: prophylactic anti-viral doses such as topical trifluorothymidine or oral aciclovir 400 mg twice daily given together with a topical corticosteroid such as 1% prednisolone eye drops every 2 h. Topical corticosteroids were then tapered every 1-2 weeks.
2,4
• For endothelial HSK: aciclovir 400 mg five times daily plus a topical corticosteroid five times daily.
9
• For prophylaxis: aciclovir 400 mg twice daily for at least a year reduced the rate of epithelial and stromal HSK episodes. 7 As available RCTs did not evaluate valaciclovir, an equivalent dose to aciclovir was used. For therapeutic indications, the equivalent valaciclovir dose for aciclovir 400 mg 3-5 times daily was valaciclovir 500 mg two to three times daily.
20, 21 For prophylaxis, the equivalent valaciclovir dose was 500 mg once daily 22 ( Table 2 ). The main study outcomes were the initial antiviral therapy prescribed and proportion of patients receiving initial anti-viral therapy in line with the 'guidelines'.
Statistical analysis
Descriptive statistics were used to summarize all continuous and categorical variables. A P value <0.05 was considered statistically significant. The statistical software used was IBM SPSS Statistics Desktop Version 22 (IBM Corp, Armonk, NY).
RESULTS
After cross-referencing the data sets, 1765 medical records were identified and reviewed (Table 1) . After applying the inclusion and exclusion criteria, 301 eyes from 296 patients were included. Of these, 186 (63%) were retrieved from pharmacy records, 107 (36%) from HSV PCR records and 3 (1%) from ICD coding data. The reasons for exclusion were blepharitis/conjunctivitis (n = 675, 38%), microbial keratitis (n = 171, 10%), herpes zoster keratitis (n = 80, 5%) and other diagnosis (n = 543, 31%). HSV PCR was routinely requested at our institution in patients with presumed HSK diagnoses but also for several other eye conditions. Therefore, a large number of cases of blepharitis/conjunctivitis, and other diagnosis such as non-infective keratitis, punctate epithelial erosions, epithelial defect, corneal abrasion, episcleritis, anterior uveitis, herpetic neuralgia and HSV-like skin lesions were excluded as the patients did not have HSK.
Anti-virals are not only prescribed for HSK but also for other ocular viral infections. From the pharmacy records, patients with herpes zoster virus and cytomegalovirus infections, and HSK with associated bacterial infection were excluded.
From the 301 eyes, 256 (85%) eyes received antiviral therapy for therapeutic indications and 45 (15%) eyes for prophylaxis. The demographics of the patients are shown in Table 3 . Five patients were diagnosed with bilateral HSK at presentation.
Therapeutic indication
Of the 256 eyes treated with anti-virals for a therapeutic indication, 141 (55%), 22 (9%), 22 (9%), 18 (7%) and 53 (21%) eyes were diagnosed with epithelial, stromal with ulceration, stromal without ulceration, endothelial HSK and herpetic keratouveitis, respectively.
Of the 141 eyes with epithelial HSK, 113 (80.1%) received topical aciclovir five times daily. The remaining 28 eyes (18.9%) were either given oral anti-virals or a combination of oral and topical antivirals (Table 4) . Valaciclovir was the most commonly prescribed oral anti-viral, with doses ranging from 500 mg to 1 g once to three times daily. Topical corticosteroids were prescribed with anti-viral agents in 13 of the 141 (9.3%) eyes (Table 5 ). Preserved dexamethasone 0.1% ophthalmic suspension (Maxidex, Alcon, Fort Worth, TX, USA) (n = 3 eyes), preserved prednisolone acetate 1% and phenylephrine hydrochloride 0.12% ophthalmic suspension (Prednefrin Forte, Allergan, Sydney, Australia) (n = 3 eyes) and unpreserved dexamethasone sodium phosphate 0.1% ophthalmic solution (Minims dexamethasone sodium phosphate) (n = 3 eyes) were the preferred agents. Topical corticosteroids were prescribed at varying frequencies, including once, twice, three times, four times per day, once at night or every 1 or 2 h. Indications for prescribing topical corticosteroids included previous HSK episodes (n = For stromal HSK, 18 of the 44 (40.9%) eyes received topical aciclovir five times daily and 9 of 44 (20.5%) eyes received valaciclovir 500 mg twice daily. Oral, topical or a combination of topical and oral anti-viral agents was given to 17 eyes (38.6%) ( Table 4 ). In addition, 16 (37.2%) eyes received topical corticosteroids (Table 5 ). Preserved dexamethasone 0.1% ophthalmic suspension (n = 6 eyes) was the most frequently prescribed topical corticosteroid.
For endothelial HSK, 14 (77.8%) eyes received valaciclovir in doses ranging from 500 mg twice daily to 1 g twice or three times daily. Two of 18 (11.1%) eyes received topical aciclovir five times daily and the remaining two (11.1%) eyes oral aciclovir twice or five times daily (Table 4) . Seventeen of the 18 (94%) also received topical corticosteroids (Table 5 ). Preserved prednisolone acetate 1% and phenylephrine hydrochloride 0.12% ophthalmic suspension was the most common topical corticosteroid; it was prescribed in eight eyes at a frequency of three, four or six times or every hour daily.
For keratouveitis, 30 of 53 (56.6%) eyes received valaciclovir in doses ranging from 500 mg to 1 g once, twice or three times daily. Five eyes (9.4%) received oral aciclovir in doses ranging from 200 to 400 mg five times daily. Eleven eyes (20.8%) received topical aciclovir five times daily and the remaining seven eyes (13.2%) combined oral and topical anti-virals (Table 4) . Topical corticosteroids were also given in 33 eyes (62%) ( Table 5 ). Preserved prednisolone acetate 1% and phenylephrine hydrochloride 0.12% ophthalmic suspension was the most common medication (n = 21 eyes), prescribed at frequencies including four and six times, every hour and every 2 h.
Adherence to the 'guidelines' was found in 125 of the 141 (89%) eyes with epithelial HSK, 2 of the 22 (9%) eyes with stromal HSK without ulceration and 6 of 18 (33%) eyes with endothelial HSK. A comparison to guidelines for stromal HSK with ulceration and keratouveitis could not be made, as no treatment recommendations for these conditions were found in the literature when this study was started.
Prophylactic indication
Fifty-four prophylactic indications for anti-viral therapy were identified in 44 patients. Ten patients had two prophylactic indications. Indications included prior stromal HSK (n = 17), prior keratouveitis (n = 20), prior corneal graft (n = 16) and unclear (n = 1) ( Table 6 ).
Valaciclovir 500 mg once daily in 29 (66%) patients was the most commonly prescribed anti-viral agent followed by valaciclovir 500 mg twice daily in five (11%) patients. Six (14%) patients received oral aciclovir in doses ranging from 200 to 400 mg once to three times daily. Topical anti-virals were given in two patients. One patient (2%) received topical aciclovir five times daily and another (2%) trifluorothymidine as needed. Two (4%) patients received a combination of oral and topical anti-virals. Thirty-nine of the 45 (88%) eyes also received a topical corticosteroid as initial therapy (Table 5) . One eye received two topical corticosteroids, hydrocortisone ointment and preserved prednisolone acetate 1%. The most common topical corticosteroid agents were preserved fluorometholone 0.1% ophthalmic suspension (FML, Allergan, Sydney, Australia) and preserved dexamethasone 0.1% ophthalmic suspension prescribed at frequencies of once, twice, three, four, six times, every 2 h or every other day.
Adherence to the 'guidelines' was found in 31 of the 45 (69%) eyes receiving either valaciclovir 500 mg once daily or aciclovir 400 mg twice daily.
DISCUSSION
This study investigated whether the evidence from RCTs and systematic reviews for HSK available up to December 2013 has been translated into clinical practice for 2012-2013 in a quaternary eye care centre in Sydney, Australia. In this study, 133 of 256 (52%) eyes with a therapeutic indication and 31 of 45 (69%) eyes with a prophylactic indication were prescribed the recommended anti-viral agents for HSK. Overall, 164 of 301 eyes (54%) followed the literature-based evidence. A comparison to guidelines was not made for eyes with stromal HSK with ulceration and keratouveitis as there were no treatment recommendations available in the literature when the study started. Prescribing patterns for anti-viral therapy to treat and prevent recurrence of HSK were diverse in this study. Seven initial antiviral therapeutic regimens were identified, including topical aciclovir, trifluorothymidine, oral aciclovir, valaciclovir, oral aciclovir and topical aciclovir, valaciclovir and topical aciclovir, and valaciclovir and trifluorothymidine. Frequencies of the anti-virals varied according to the type of keratitis.
A study conducted in France also reported a wide variety of therapeutic interventions for new and recurrent HSK, suggesting a lack of consensus regarding appropriate anti-viral therapy. 23 In France, 18 anti-viral therapies were identified including one or two local agents (aciclovir, trifluorothymidine, ganciclovir, idoxuridine); oral agents (valaciclovir and aciclovir); or a combination of one 2) † Percentage (%) calculated from total cases of each indication shown on column header. ‡ Topical steroids were prescribed daily. BD, twice daily; n, number of eyes; OD, once daily; QID, four times daily; TDS, three times daily.
or two oral and one or two local agents for 357 patients. Notable therapies included 31% local therapy with one agent (aciclovir or trifluorothymidine), 13% oral therapy (aciclovir or valaciclovir) and 20% oral therapy and topical aciclovir. 23 In contrast, in our study, 50% of the eyes received local therapy (aciclovir or trifluorothymidine), 42% oral therapy (aciclovir or valaciclovir) and 8% oral therapy and topical aciclovir. Valaciclovir was preferred as oral therapy and topical aciclovir as local treatment at the Sydney Eye Hospital contrary to the study in France where ophthalmologists used a myriad of treatments many of which are not available in Australia. The use of valaciclovir in our study, most likely reflects its availability and the prescribing clinician's preference to increase compliance with reduced frequency of dosing compared to aciclovir.
The wide disparity in initial anti-viral therapy found in this study indicates that the 'guidelines' have not translated easily into routine clinical practice. Adherence to the 'guidelines' was found in 89% of epithelial HSK cases, 9% of stromal without ulceration HSK cases, 33% of endothelial HSK cases and 69% of HSK prophylaxis cases. Diversity of initial anti-viral therapy may be related to a number of factors. The 'guidelines' included medications such as oral aciclovir and trifluorothymidine, which are not routinely prescribed for HSK in Australia. Since the release of HEDS recommendations in 1990s, other medications such as valaciclovir and ganciclovir have become widely available in some parts of the world. Indeed, since our study the American Academy of Ophthalmology has released guidelines for HSK management. 24 Although, ganciclovir and trifluorothymidine are recommended in the United States, they are not easily accessible in Australia. Further, there are no studies evaluating the efficacy of valaciclovir, which is widely used these days for treating HSK. Valaciclovir is an aciclovir pro-drug, and although the equivalent dose to aciclovir has been determined, it is not clearly understood by clinicians, as they prescribe various valaciclovir dosages for HSK and often follow treatment regimens learnt during their training, some of which may have become superseded by newer drugs. 25 Additionally, strong clinical evidence is not available to guide anti-viral therapy for stromal keratitis with ulceration, endothelial HSK and keratouveitis. In the present study, doctors prescribed higher doses of anti-viral medications than recommended, which can cause side effects and increase costs for patients.
A myriad of topical corticosteroid preparations and their frequencies were prescribed in this study. Topical corticosteroids were prescribed with antiviral agents in 13 of 141 (9%) eyes with epithelial HSK and 66 of 115 (57%) eyes with stromal, endothelial HSK or keratouveitis; and in 39 of 45 (77%) eyes on prophylaxis. Topical corticosteroids are the mainstay of treatment for stromal, endothelial HSK and keratouveitis. Reasons for the reluctance to prescribe topical corticosteroids may include lack of confidence or knowledge in diagnosing HSK, insufficient senior supervision and concerns regarding adequate follow-up of patients. Stromal HSK, specifically, can mimic bacterial or fungal keratitis with presence of dense corneal infiltration and ulceration, as well as hypopyon. Additionally, bacterial superinfection is not uncommon in this group. The low rate of topical corticosteroid use for this subset of HSK in our centre may reflect a reluctance to prescribe steroids for fear of worsening the outcome of possible bacterial or fungal keratitis.
Identifying HSK prescribing trends highlights the need for and contributes to the development of local treatment guidelines. Standardized initial anti-viral therapy based on clinical evidence will reduce side effects, complications and HSK recurrences and reduce expensive HSK treatment costs. 26 In Australia, aciclovir is available in tablets of 200 mg and in 3% ointment (Zovirax, GlaxoSmithKline, Abbotsford, Australia), and valaciclovir in tablets of 500 mg. The cost of these medications at the Sydney Eye Hospital is less than in a community pharmacy due to a hospital contract with the pharmaceutical company. Moreover, the price of valaciclovir has decreased significantly during the last 2 years, coinciding with the expiry of the patent. Generic brands of valaciclovir are now available with a lower cost. The advantages of valaciclovir over aciclovir include less frequent dosing (two to three times compared to five times for acute therapy and once daily compared to twice for prophylaxis), a lactose-free generic formulation, reducing stomach discomfort and nausea in those with lactose intolerance, 25 and based on Sydney Eye Hospital contract pricing, a slight lower cost of a 7-day treatment (500 mg twice daily) over aciclovir. The disadvantage is the cost of the long-term valaciclovir treatment, which is double that of aciclovir. Despite the cost, valaciclovir is the preferred agent for the management of HSK. Further studies could explore how local guidelines are developed based on the results of this study and on recent HSK treatment guidelines 24 ; and implemented in clinical settings, and how prescriber's behaviour can be changed. Randomized controlled trials are needed to compare dosages and frequencies of aciclovir vs. valaciclovir for stromal, endothelial HSK and keratouveitis.
The major limitation of the present study is its retrospective nature. There is documentation bias as the study relied on the completeness of the medical records. This type of study is prone to misclassification bias as the investigators may have classified patients with HSK differently to the ophthalmologist managing the patient. This study design is appropriate to evaluate the prescribing trends of HSK as it documents prescriber behaviour in a quaternary hospital setting and is a starting point to generate hypotheses to be tested in future studies. Additionally, the study was based at a single site. The Sydney Eye Hospital is a quaternary eye referral centre, which receives on average five patients per week with HSK from different regions of New South Wales. Trainee ophthalmologists at the Sydney Eye Hospital rotate to centres across New South Wales.
In conclusion, there was a large diversity of initial anti-viral therapy for HSK in the quaternary referral eye hospital. Overall, 54% (164/301) of eyes received the recommended therapy from the 'guidelines'. The study highlights the moderate clinical implementation of the 'guidelines', lack of updated studies evaluating new treatments for HSK and the importance of developing Australian guidelines for the management of HSK based on clinical evidence to improve patient care and rationalize health resources.
